Hyperspectral imaging in head and neck tumors and malignant non-melanotic skin tumors
Recruiting
- Conditions
- Malignant neoplasm of the oral cavity, oropharynx, hypopharynx, larynxnon-melanotic skin tumor in the head and neck areaC14.8C10.8C32.8C13.8D23.9Overlapping lesion of lip, oral cavity and pharynxOverlapping lesion of oropharynxOverlapping lesion of larynxOverlapping lesion of hypopharynx
- Registration Number
- DRKS00033009
- Lead Sponsor
- niversitätsklinik Jena, Klinik für Hals-, Nasen- und Ohrenheilkunde
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with (suspected) head and neck tumor
Patients with (suspected) non-melanotic skin tumor in the head and neck area
Written informed consent of the patient to participate in the study
Exclusion Criteria
Absence of informed consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary aim of the study is to test the suitability of HSI imaging for the acquisition of HSI image data of tumors in vivo.
- Secondary Outcome Measures
Name Time Method The secondary objective is to obtain initial data for the identification of features in the HSI image data that correlate with annotations (pathological findings). This will be used to develop an artificial intelligence (AI) model for tumor diagnostics.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular signatures does hyperspectral imaging detect in head and neck squamous cell carcinomas?
How does hyperspectral imaging compare to histopathology for diagnosing non-melanotic skin tumors in the oropharynx?
Which angiogenesis biomarkers correlate with tumor heterogeneity in DRKS00033009 hyperspectral imaging data?
What adverse events are associated with hyperspectral imaging in C14.8 and C10.8 head and neck tumor diagnostics?
How can hyperspectral imaging enhance targeted therapy monitoring for D23.9 overlapping lip and oral cavity lesions?